Nature Reviews Clinical Oncology - Table of Contents alert Volume 10 Issue 6

TABLE OF CONTENTS
June 2013 Volume 10 Number 6
Impact Factor 9.113 *	In this issue Research Highlights News and Views Reviews Perspectives Also this month  Featured article: Access to cancer medications in low- and middle-income countries Gilberto de Lima Lopes, Jonas A. de Souza & Carlos Barrios
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
nature.com webcasts Macmillan Science Communication presents a custom webcast on: Personalized medicine: A framework for clinical genome sequencing in cancer Thursday May 30th 2013 10am PDT / 1pm EDT / 6pm BST / 7pm CEST Register for the free webcast followed by our live Q and A session Sponsored by:
RESEARCH HIGHLIGHTS Top Gastrointestinal cancer: Turning up trumps for new CRC subtypes Published online: 07 May 2013 p303 | doi:10.1038/nrclinonc.2013.71 PDF Genetics: New classification for endometrial cancer puts genes in POLE position Published online: 14 May 2013 p304 | doi:10.1038/nrclinonc.2013.82 PDF Haematological cancer: New standard of care? Published online: 23 April 2013 p305 | doi:10.1038/nrclinonc.2013.69 PDF Urological cancer: Second-line option for metastatic RCC Published online: 30 April 2013 p305 | doi:10.1038/nrclinonc.2013.74 PDF Genetics: The AML mutational landscape Published online: 14 May 2013 p305 | doi:10.1038/nrclinonc.2013.81 PDF Chemotherapy: Final ACT for standard of care in anal cancer? Published online: 23 April 2013 p306 | doi:10.1038/nrclinonc.2013.68 PDF Risk factors: Pour yourself a glass—survival unaffected Published online: 23 April 2013 p306 | doi:10.1038/nrclinonc.2013.70 PDF IN BRIEF Breast cancer: Adverse effects and mammographic density as markers | Gastrointestinal cancer: Reduced risk of gastric cancer associated with statins | Epidemiology: Epidemic rates of cancer incidence in Latin America PDF Clinical Oncology JOBS of the week Clinical Senior Lecturer in Radiation Oncology Queen's University Belfast Postdoc Position in Cancer Research Charité — Universitätsmedizin Berlin - MKFZ Faculty Position Vanderbilt Ingram Cancer Center Senior Expert Statistician Merck Group Postdoctoral Scientist University Of Alabama At Birmingham - Radiation Oncology More Science jobs from Clinical Oncology EVENT Molecular Biology in Clinical Oncology 07.21.13 US More science events from
NEWS AND VIEWS		Top
Urological cancer: Walking the tightrope of survival and quality of life with ADT Matthew J. Resnick Published online: 07 May 2013 p307 | doi:10.1038/nrclinonc.2013.78 A recent study has highlighted the risks and benefits associated with the administration of intermittent androgen deprivation therapy in patients with metastatic prostate cancer. Although there are improvements in many quality-of-life domains, these improvements must be carefully weighed against the potential harms of intermittent androgen deprivation therapy in this patient population. Full Text | PDF
Sarcoma: Primary retroperitoneal sarcoma—predicting survival Murray F. Brennan Published online: 07 May 2013 p309 | doi:10.1038/nrclinonc.2013.73 Nomograms have been constructed to provide patient-specific predictions for overall survival and disease-free survival after resection for patients with primary localized retroperitoneal soft tissue sarcoma, by combining data registered across three institutional databases. However, whether overall survival, or disease-free survival, is a more useful predictor is disputable. Full Text | PDF
Breast cancer: Risk of heart disease after radiotherapy—cause for concern Timothy M. Zagar & Lawrence B. Marks Published online: 23 April 2013 p310 | doi:10.1038/nrclinonc.2013.59 Radiotherapy is known to cause heart disease. A recent analysis challenges several long-held tenets, indicating that radiation-induced cardiotoxicity might occur at lower doses, and earlier, than generally believed. We must be mindful of this toxicity and limit cardiac radiation dose as much as possible. Full Text | PDF
Targeted therapies: HER2-positive breast cancer—sifting through many good options Ian E. Krop Published online: 30 April 2013 p312 | doi:10.1038/nrclinonc.2013.72 The addition of lapatinib to paclitaxel improves survival in patients with newly diagnosed HER2-positive metastatic breast cancer, further validating the importance of HER2 signalling as a target in this cancer subtype. However, the availability of other more-effective and less-toxic HER2-targeted therapies limits the clinical usefulness of the regimen. Full Text | PDF
REVIEWS		Top
Access to cancer medications in low- and middle-income countries Gilberto de Lima Lopes, Jr, Jonas A. de Souza & Carlos Barrios Published online: 09 April 2013 p314 | doi:10.1038/nrclinonc.2013.55 For patients in low and middle-income countries (LMICs), many of the advances in medical oncology enjoyed in the developed world are nothing but an aspiration for the future. However, as Gilberto Lopes Jr and colleagues describe, LMICS are using generic and biosimilar drugs, expanding participation in clinical trials, implementing universal health-care schemes, using compulsory licensing schemes and increasing public-private partnerships to increase access to cancer medications for their citizens. Abstract | Full Text | PDF
Advanced-stage pancreatic cancer: therapy options Jens Werner, Stephanie E. Combs, Christoph Springfeld, Werner Hartwig, Thilo Hackert & Markus W. Büchler Published online: 30 April 2013 p323 | doi:10.1038/nrclinonc.2013.66 Although surgery is a requirement for a potential cure from pancreatic cancer, it is usually diagnosed at a late stage, when surgical intervention is not straightforward. This Review article outlines the controversies surrounding the treatment options for patients with advanced-stage pancreatic cancer, from surgery through to chemotherapy, radiotherapy, targeted agents and palliative care. Abstract | Full Text | PDF
Lung cancer chemoprevention: current status and future prospects Robert L. Keith & York E. Miller Published online: 21 May 2013 p334 | doi:10.1038/nrclinonc.2013.64 Lung cancer is the leading cause of cancer death in the world. Although smoking cessation will have the greatest impact on lung cancer development, chemoprevention could prove to be very effective. The authors discuss the principles of chemoprevention, including data from preclinical models, completed clinical trials and observational studies, and describe new treatments for novel targeted pathways and future chemopreventive efforts. Abstract | Full Text | PDF
Current modalities of accelerated partial breast irradiation John A. Cox & Todd A. Swanson Published online: 30 April 2013 p344 | doi:10.1038/nrclinonc.2013.65 In selected patients with early stage breast cancer, accelerated partial breast irradiation (APBI) has emerged as an alternative treatment option to whole breast irradiation. The authors of this article review the available modalities, patient selection criteria and consensus guideline recommendations, and current controversies in APBI, and discuss why it has become an accepted therapy for suitably selected patients outside of clinical trials. Abstract | Full Text | PDF
PERSPECTIVES		Top
OPINION Taxane benefit in breast cancer—a role for grade and chromosomal stability Roger P. A'Hern, Mariam Jamal-Hanjani, A. Marcell Szász, Stephen R. D. Johnston, Jorge S. Reis-Filho, Rebecca Roylance & Charles Swanton Published online: 07 May 2013 p357 | doi:10.1038/nrclinonc.2013.67 In this Perspectives article, the authors propose that lower histological grade in breast cancer might be a hallmark of relative chromosomal stability, which in turn might be predictive of additional benefit from taxane-based chemotherapy in women with oestrogen-receptor-positive cancer. They interpret published data to on the relationships between tumour grade, chromosomal instability and intratumour heterogeneity and discuss the potential use of chromosomal instability to tailor therapy. Abstract | Full Text | PDF | Supplementary information
Advertisement
Take part in our reader survey for a chance to win a MacBook Air As a reader of NPG's clinical and society-owned journals, we invite you to take part in a survey on your use of our journals and their associated websites. Take the survey and be entered into a prize draw for a MacBook Air* *Terms & conditions apply
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2011. Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.